STRS Ohio’s BioCryst Pharmaceuticals BCRX Stock Holding History

STRS Ohio’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$891K	Buy	+89,100	New	+$806K	﹤0.01%	785
2025 Q4	–	Sell	-40,700	Closed	-$309K	–	2186
2025 Q3	$309K	Hold	40,700	–	–	﹤0.01%	1320
2025 Q2	$365K	Buy	40,700 +2,900	+8%	+$27K	﹤0.01%	1435
2025 Q1	$284K	Buy	37,800 +29,500	+355%	+$238K	﹤0.01%	1423
2024 Q4	$62.4K	Buy	+8,300	New	+$63K	﹤0.01%	1701
2022 Q4	–	Sell	-1,500	Closed	-$18K	–	1983
2022 Q3	$18K	Buy	+1,500	New	+$19.3K	﹤0.01%	1934
2022 Q2	–	Sell	-2,000	Closed	-$32K	–	2052
2022 Q1	$32K	Buy	+2,000	New	+$32.1K	﹤0.01%	1999
2021 Q4	–	Sell	-3,400	Closed	-$48K	–	2200
2021 Q3	$48K	Buy	+3,400	New	+$53.6K	﹤0.01%	2075
2020 Q3	–	Sell	-16,400	Closed	-$78K	–	2194
2020 Q2	$78K	Buy	+16,400	New	+$65.5K	﹤0.01%	1835

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

STRS Ohio's BCRX Position: Q2 2026 in Review

STRS Ohio opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 89,100 shares worth $891K. The stake represents ﹤0.01% of the portfolio and ranks #785 among its holdings. This is a return to the name: STRS Ohio previously reported a position in BCRX as recently as Q3 2025.

STRS Ohio first reported a position in BCRX in Q2 2020 and has held it in 9 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

STRS Ohio held 89,100 shares of BioCryst Pharmaceuticals worth $891K as of Q2 2026.
BioCryst Pharmaceuticals was a new STRS Ohio position in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #785 holding.
STRS Ohio first reported a position in BioCryst Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.